ACRES Commercial Realty Reports Q1 Results

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: Apr 30 2026

0mins

ACR+0.3%

Explore Agentic TradingLet AI Trade for You

Source: PRnewswire

Financial Performance: For the quarter ended March 31, 2026, ACR reported a GAAP net loss of $1 million, translating to a diluted loss of $0.16 per share, indicating challenges in profitability that may affect investor confidence.
Loan Portfolio Growth: In Q1, ACR added $496 million in high-quality loans to its portfolio, alongside $571 million from Q4 2025, facilitating the successful closing of a $1 billion CRE CLO in February, demonstrating the company's active engagement and financing capabilities in the market.
Asset Disposal Gains: The company realized a gain of $3.3 million from the sale of a real estate investment this quarter, which not only improved cash flow but also provided funding for future investments, showcasing flexibility in asset management.
Investor Communication: ACR will host a conference call on April 30, 2026, to discuss its Q1 results, enhancing interaction with investors and aiming to improve transparency and market trust.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ACR?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ACR

About ACR

ACRES Commercial Realty Corp. is a real estate investment trust. The Company is primarily focused on originating, holding and managing commercial real estate mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. Its objective is to provide its stockholders with total returns over time, including the payment of quarterly distributions when approved by its board of directors, and capital appreciation, while seeking to manage the risks associated with its investment strategies. It invests in CRE whole loans and CRE equity investments. The Company is externally managed by ACRES Capital, LLC, a subsidiary of ACRES Capital Corp., a private commercial real estate lender dedicated to nationwide middle market commercial real estate lending with a focus on multifamily, student housing, hospitality, industrial and office property in the United States markets.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

ACRES Commercial Realty Corp. Declares Cash Dividends on Preferred Stock

2 hours agoPRnewswire

Dividend Announcement: ACRES Commercial Realty Corp.'s Board of Directors declared a cash dividend of $0.5993994 per share on its 8.625% Fixed-to-Floating Series C Cumulative Redeemable Preferred Stock, reflecting a rate of 9.59039%, which is based on the three-month Term SOFR plus a spread of 5.927% per annum, demonstrating the company's commitment to shareholder returns.
Payment Date: This cash dividend will be payable on July 30, 2026, to holders of record on July 1, 2026, ensuring that shareholders receive their earnings promptly, which enhances investor confidence in the company.
Series D Dividend: Additionally, the company will pay a cash dividend of $0.4921875 per share on its 7.875% Series D Cumulative Redeemable Preferred Stock, further reflecting the company's sound capital management and focus on shareholder value.
Company Overview: ACRES Commercial Realty Corp. focuses on originating, holding, and managing commercial real estate mortgage loans and may hold equity investments in commercial real estate properties through direct ownership and joint ventures, showcasing its diversified investment strategy in the U.S. market.

Multiple Company Sale Transactions and Shareholder Rights

May 12 2026PRnewswire

Transaction Overview: Catalyst Pharmaceuticals, Inc. is being sold to Angelini Pharma S.p.A. for $31.50 per share in cash, providing shareholders with immediate cash returns and enhancing investor confidence in the company's future value.
UniFirst Sale: UniFirst Corporation is being sold to Cintas Corporation for $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, offering shareholders a flexible option that may attract various types of investors.
RE/MAX Deal: RE/MAX Holdings, Inc. has a sale proposal that includes either 5.152 shares of the combined company or $13.80 in cash per share, aiming to provide shareholders with diversified exit strategies and enhance overall return potential.
Legal Rights: Halper Sadeh LLC is seeking increased consideration and additional disclosures on behalf of shareholders, indicating a proactive stance in protecting shareholder rights, which may influence future corporate governance structures.

Investor Rights Law Firm Investigates Multiple Companies for Potential Violations

May 08 2026PRnewswire

Investigation Background: Halper Sadeh LLC is investigating Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) regarding its sale to Angelini Pharma S.p.A. for $31.50 per share, as potential violations of shareholder rights may exist, prompting shareholders to understand their rights and options.
Transaction Details: TruBridge, Inc. (NASDAQ:TBRG) is being sold to Inventurus Knowledge Solutions, Inc. for $26.25 per share in cash, with Halper Sadeh LLC urging shareholders to be aware of potential legal rights and compensation opportunities.
Merger Impact: Following the proposed transaction, Modiv Industrial, Inc. (NYSE:MDV) shareholders are expected to own approximately 11% of the combined company, and Halper Sadeh LLC may seek increased compensation for shareholders.
Legal Support: Halper Sadeh LLC represents investors globally, focusing on legal remedies for securities fraud and corporate misconduct, emphasizing its successful track record in implementing corporate reforms and recovering funds for defrauded investors.

Investor Rights Law Firm Investigates Multiple Companies

May 04 2026PRnewswire

Investigation Focus: Halper Sadeh LLC is investigating Esperion Therapeutics, Inc. (NASDAQ:ESPR) for potential violations of federal securities laws due to its sale to ARCHIMED for $3.16 per share, which may impact shareholder rights and potential gains.
Shareholder Rights: The firm encourages Esperion shareholders to reach out to discuss their rights and options, indicating potential losses in benefits compared to ordinary shareholders in the transaction.
Transaction Terms: Global Business Travel Group, Inc. (NYSE:GBTG) is being sold to Long Lake Management for $9.50 per share in cash, with Halper Sadeh LLC potentially seeking increased compensation for shareholders, highlighting concerns over the transaction terms.
Merger Investigation: The merger of ACRES Commercial Realty Corp. (NYSE:ACR) with ACRES Capital Corp. is also under investigation, with Halper Sadeh LLC possibly advocating for more disclosures and rights for shareholders, emphasizing the need for transparency in merger transactions.

ACRES Commercial Realty Q1 2026 Earnings Call Insights

Apr 30 2026seekingalpha

Asset Sale Gains: ACRES sold a real estate investment this quarter, realizing a $3.3 million GAAP and EAD gain, which not only bolstered liquidity but also provided funding for subsequent loan investments.
New Securitization Project: The company completed a $1 billion CRE securitization with a leverage of 86.5%, expected to yield full benefits in Q2, significantly enhancing asset management revenue and overall financial performance.
Loan Portfolio Growth: As of March 31, ACRES increased its loan portfolio to $2.2 billion with new commitments of $495.6 million, resulting in a net increase of $374.4 million, indicating the company's expansion capability and improved credit quality in the market.
Internalization Merger Plan: ACRES plans to vote on an internalization merger at the annual shareholder meeting on June 22, with management retaining over 40% ownership post-merger, expected to drive growth in non-balance sheet-related revenues through asset management activities.